DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Gluz O, Nitz U, Liedtke C. et al.
Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT‑TN phase II trial.
J Clin Oncol; 2018
36 (Suppl). Abstr. 573
Access:
We do not assume any responsibility for the contents of the web pages of other providers.